A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A group of outside advisers to the U.S. Centers for Disease Control and Prevention voted 5-2 to recommend the use of a new shot that can protect babies from respiratory syncytial virus, adding an ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

Abrysvo also is approved for prevention of LRTD caused by RSV in adults ages 18 to 59 years who are at increased risk, and for immunization in pregnancy at 32 to 36 weeks' gestational age for the ...

Queensland’s Chief Health Officer has praised the new immunisation program that has protected hundreds of Queensland babies from Respiratory Syncytial Virus (RSV), as flu and Covid-19 cases ...

Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has approved ENFLONSIA™ for the prevention of respiratory syncytial virus lower ...

Fiona Havers, who oversaw CDC respiratory virus data, ... led the CDC’s surveillance of hospitalizations for coronavirus and respiratory syncytial virus (RSV), ...